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Abstract (250 words) 
Epidemiological studies suggest a protective role of omega-3 poly-unsaturated fatty acids (n-3 PUFA) against 
Alzheimer’s disease (AD). However, most intervention studies of supplementation with n-3 PUFA have yielded 
disappointing results. One reason for such discordant results may result from inadequate targeting of individuals 
who might benefit from the supplementation, in particular because of their genetic susceptibility to AD. The 4 
allele of the apolipoprotein E gene (ApoE) is a genetic risk factor for late-onset AD. ApoE plays a key role in the 
transport of cholesterol and other lipids involved in brain composition and functioning. The action of n-3 PUFA 
on the aging brain might therefore differ according to ApoE polymorphism. The aim of this review is to examine 
the interaction between dietary fatty acids and ApoE genotype on the risk for AD. 
Carriers of the 4 allele tend to be the most responsive to changes in dietary fat and cholesterol. Conversely, 
several epidemiological studies suggest a protective effect of long-chain n-3 PUFA on cognitive decline only in 
those who do not carry the 4 but with inconsistent results. An intervention study showed that only non-carriers 
had increased concentrations of long-chain n-3 PUFA in response to supplementation. The mechanisms 
underlying this gene-by-diet interaction on AD risk may involve impaired fatty acids and cholesterol transport, 
altered metabolism of n-3 PUFA, glucose or ketones, or modification of other risk factors of AD in 4 carriers. 
Further research is needed to explain the differential effect of n-3 PUFA on AD according to ApoE genotype. 
 





Prevention of age-related cognitive decline and dementia has become a public health challenge. Dementia results 
from a dynamic interaction between genetically determined, non-modifiable, pathological processes and 
environmental exposures that are potentially preventable or reversible [1]. Nutrition, a major lifelong 
environmental factor, offers promising perspectives for the prevention of late-life dementia. Long-chain poly-
unsaturated fatty acids (PUFA) are major components of neuron membranes where they exert a functional and 
structural role [2-3]. Broadly speaking, PUFA of the omega-3 (n-3) and omega-6 (n-6) series have opposite 
effects on inflammation, atherogenesis, thrombosis, and gene expression, and their respective proportions 
influence the physical properties of biological membranes where they are incorporated [4]. A competition exists 
between the n-3 and n-6 families for the synthesis of long-chain PUFA from their respective precursors alpha-
linolenic and linoleic acids [4]. Moreover, the biosynthesis of long-chain n-3 PUFA is very limited in humans 
[5]. These must therefore be obtained through diet. Fish and seafood are the main dietary source of long-chain n-
3 PUFA under the form of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [6]. 
Several prospective epidemiological studies have suggested a protective role of fish consumption [7-11] or 
dietary n-3 PUFA [9] against risk of dementia or Alzheimer’s disease (AD). However, conflicting results exist as 
well [12-15]. Moreover, most intervention studies based on supplementation with n-3 PUFA have failed to 
evidence any protective effect on AD [16-17] or cognitive decline [18-20] except in some patients with very 
mild cognitive impairment [16, 21-22]. We examined the reasons for such inconsistencies in a recent review 
[23]. A particular explanation for these discordant results may lie in ineffective targeting of individuals who 
might benefit from high doses of n-3 PUFA, in particular because of their genetic susceptibility to AD. The 4 
allele of the apolipoprotein E gene (ApoE) is the main genetic risk factor for late-onset AD [24]. The ApoE plays 
a key role in the transport of cholesterol and other lipids involved in brain composition and functioning [25]. The 
action of n-3 PUFA on the aging brain might therefore differ according to ApoE polymorphism, suggesting a 
gene-environment interaction. In this review we examine the interaction between dietary n-3 PUFA and ApoE 
genotype on the risk for AD at the light of biological data and human studies. 
 
2) Role of ApoE genotype in AD 
Despite the recent discovery of susceptibility genes for AD thanks to Genome Wide Assessment of large 
population-based samples, the main genetic risk factor for sporadic late-onset AD remains by far the ApoE4 
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allele (ApoE4) [26]. The ApoE gene has three different alleles: 2, 3 and 4, that give rise to six genotypes: 
 and 4/4. ApoE3 is the most common isoform [27]. The frequency of the ApoE4 
decreases following a North-to-South gradient in normal middle-aged populations as well as in patients with 
late-onset AD [28]. A meta-analysis showed that the relative increase in the frequency of ApoE4 in patients with 
AD compared with controls is substantially less in African Americans (32.2% vs. 19.0%) than Caucasians 
(36.7% vs. 13.6%) [29]. The ApoE4 increases the risk of AD by 15 times in Caucasian homozygotes [29]. 
Although ApoE4 is the major genetic risk factor for AD, its mode of action remains partly unknown [30] and 
several mechanisms have been proposed [27]. Indeed, ApoE4 is the only molecule that has been associated with 
all the biochemical disturbances characteristic of the disease: beta-amyloid (A) peptide deposition, tangle 
formation, oxidative stress, inflammation, lipid homeostasis deregulation, synaptic plasticity loss and cholinergic 
dysfunction [27]. ApoE4 may increase A in senile plaques and impair its clearance [30]. Recently, a study 
using voxel-based analysis of 
11
C labelled Pittsburgh compound B (PIB)- positron emitting tomography (PET) 
and magnetic resonance imaging (MRI) showed higher levels of A plaque deposition in AD patients with the 
ApoE4 allele compared to age-matched ApoE4-non carriers with similar levels of cognitive impairment and 
brain atrophy [31]. The neuropathological changes associated with AD occur as soon as 30 years of age, that is 
decades before the clinical onset of the disease, but in ApoE4 carriers the accumulation of A peptide in senile 
plaques is more pronounced at every age except in the oldest old  [32]. There is therefore a large window of 
action for environmental risk factors that will modulate the clinical expression of late-onset AD. In addition to 
their increased burden of A, ApoE4 carriers may be particularly sensitive to some environmental factors, in 
particular dietary fat. We focus here on the antioxidant and immunomodulatory/anti-inflammatory properties of 
ApoE [33] that are particularly relevant to lipid metabolism given the high susceptibility to peroxidation and the 
anti-inflammatory properties of n-3 PUFA. 
 
2.1 ApoE and oxidative stress 
Increased oxidative stress is a key feature in AD [34]. Markers of oxidative damage precede pathological 
changes in experimental models and are observed very early in the clinical course of the disease [35-36]. A is a 
potent generator of free radicals (reactive oxygen species, ROS, and reactive nitrogen species) [34]. The 
production of free radical species leads to peroxidation of membrane lipids. In synaptosomes isolated from mice 
that expressed only one of the 2, 3 or 4 human ApoE alleles, treatment with A induced a significantly higher 
increase in ROS and markers of lipid peroxidation in synaptosomes containing the 4 allele  [37]. 
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Oxidative stress results from an imbalance between production of free radicals and anti-oxidant defence 
mechanisms. These defence mechanisms involve enzymatic systems such as glutathion peroxidase (GSH-Px) 
and catalase (CAT) and non-enzymatic antioxidant nutrients including vitamin E, carotenoids and selenium. In 
vitro, the ApoE isoforms are associated with different antioxidant capacities, the highest being observed with the 
and the lowest with the 4 isoforms [38]. Plasma concentrations of vitamin E, a powerful fat-soluble 
antioxidant, vary according to ApoE genotype, the highest concentrations being found in individuals in one 
study [39]. In another study, no significant difference in vitamin E concentration was observed between ApoE4 
carriers and non-carriers in older AD patients while in control subjects vitamin E level was significantly higher 
in ApoE4 carriers [40]. However, this difference disappeared after normalization according to triglycerides (TG) 
and cholesterol levels. For the authors, this increased plasma vitamin E level in ApoE4 controls could be 
associated with retention of vitamin E in plasma lipoproteins and a functional vitamin E deficiency in peripheral 
tissues [40]. The protective effect of some dietary antioxidants may also depend on ApoE genotype. Vitamin E 
from food, but not other antioxidants, was associated with a reduced risk of AD only among individuals without 
the ApoE4 allele [41]. Conversely, higher serum beta-carotene was associated with lower risk of cognitive 
decline only in ApoE4 carriers among high-functioning older persons [42]. In an elderly Chinese cohort, carriers 
of the ApoE4 allele had significantly lower Selenium levels measured in nails [43]. 
ApoE genotype may also influence activity of enzymes involved in antioxidant defence mechanisms such as 
GSH-Px and CAT. In AD patients as well as in age-matched controls, the ApoE4 carriers had significantly lower 
activities of GSH-Px and CAT, and lower serum total antioxidant status compared to non ApoE4 carriers [44]. 
The decreased antioxidant activity of ApoE4 could therefore contribute to its association with AD [33]. 
 
2.2 ApoE and inflammation 
In AD, the accumulation of misfolded proteins leads to inflammatory damage [34]. In addition to low-grade 
inflammation associated with brain aging, Adeposition is accompanied by activation of microglia which will 
contribute to eliminate A. In turn, chronically activated microglia will release chemokines and pro-
inflammatory cytokines [34].  Acute systemic inflammation is also suspected to exacerbate chronic brain 
inflammation thereby increasing the rate of cognitive decline in AD patients [45]. The ApoE4 allele is also 
reported to directly promote inflammation which may contribute to its deleterious effect in AD [46]. The 
activation of the amyloid cascade in ApoE transgenic mice results in the activation of microgliosis and 
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astrogliosis in the hippocampus of ApoE4, but not in ApoE3 transgenic mice. This differential impact of ApoE 
genotype was limited to this brain area specifically affected in AD and was not observed in septal neurons [47]. 
Paradoxically, this exacerbation of brain inflammation linked to ApoE4 is not observed at peripheral level where 
inverse associations are reported. Indeed, in a comparative analysis of three large population-based studies, 
lower levels of plasma C-Reactive protein (CRP), a biomarker for inflammation, were observed in ApoE4 
carriers [48]. Similarly, in a population of cognitively normal Italian elderly, ApoE4 carriers had a lower risk of 
high CRP than non-carriers [49]. The same association was observed in nonagerians [50]. However, there is an 
interaction between peripheral markers of inflammation and ApoE on cognitive performance. In a cross-
sectional study conducted in older community dwellers, participants with at least one 4 allele and CRP in the 
highest tertile had the greatest odds of impaired memory [51]. This finding suggests, as already hypothesized by 
Jofre-Monseny et al. [33], that the detrimental effect of ApoE might be partly counteracted by lower levels of 
CRP. 
This large body of evidence suggests that ApoE4 is a key player in the pathogenesis of AD [27]. A large part of 
this effect might be explained by the major role of ApoE in lipid metabolism. 
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[Figure 1 here] 
 
 
Figure 1.  Metabolism of lipoproteins starting with absorption in the small intestine.  
LPL = lipoprotein lipase, HL = hepatic lipase, VLDL = very low density lipoproteins, IDL = intermediate 
density lipoproteins, LDL = low density lipoproteins 
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2.3 ApoE genotype, lipid metabolism and AD 
Most dietary fats are ingested in the form of TG. They are efficiently absorbed in the small intestine towards 
facilitated diffusion and uptaken by enterocytes in the forms of fatty acids and monoglycerides (Figure 1) [52]. 
Once fatty acids have entered the cell, they are re-esterified with glycerol back into TG and phospholipids (PL) 
for transport in the blood via chylomicrons to the liver and other tissues. All lipoproteins, with the exception of 
chylomicrons, are produced by the liver, and begin as molecules packed full with TG, with the exception of high 
density lipoprotein (HDL). Very low density lipoprotein (VLDL) is the most TG-rich lipoprotein, which through 
sequential lipolysis of TG by lipoprotein lipase leads to the formation of low density lipoprotein (LDL). 
Lipoproteins are composed of lipids and proteins named apolipoproteins which bind to specific receptors. ApoE 
is specific to LDL receptor which is at the root of cholesterol homeostasis but is also essential for normal 
catabolism of TG-rich lipoprotein constituent.  
Throughout life and increasing with age, neurons must be remodelled and repair to maintain neurotransmission 
[30]. Through its lipid transport function, ApoE plays a key role in the transport and metabolism of cholesterol, 
TG and other lipids within many organs including the brain [25, 53]. ApoE is also the main ligand for LDL 
receptors in the periphery, while in the central nervous system it is the main ligand for the LDL receptor-related 
protein [53]. In the brain ApoE plays an important role in the maintenance and repair of neurons, by distributing 
lipids necessary for proliferation, synaptogenesis and myelinisation of axons [27] 
Allelic variations in ApoE impair the protein structure, function and metabolism [54]. For instance, in ApoE4 
carriers, substitution of an amino acid changes the protein structure because of the formation of a salt bridge 
between an arginine at position 61 and a glutamic acid at position 255, causing the isoform to bind preferentially 
to VLDL [54]. 
 
2.3.1  ApoE and cholesterol 
Other mechanisms linking ApoE and risk of AD possibly involve cholesterol homeostasis in the brain since 
ApoE is its principal carrier [53]. In the brain, cholesterol has a crucial role in development of neuronal plasticity 
and function [55]. All the cholesterol used in the brain is synthesized within the central nervous system since the 
blood-brain barrier restricts direct transport of cholesterol from peripheral circulation, in the absence of vascular 
injury [55]. 
 9 
Cholesterol forms complexes with ApoE for delivery to neurons and is an essential component of neuronal
 
membranes where it is concentrated in lipid rafts [34]. Rafts are membrane micro-environments for the assembly 
of β-secretases and γ-secretases and processing of amyloid precursor protein into Aβ [34]. ApoE isoforms 
influence the composition of membrane lipid rafts [56]. ApoE4 is the least effective of the three isoforms in 
promoting healthy lipid membrane turnover. ApoE4 also enhances Aβ production and decreases its clearance, 
leading to higher aggregation of Aβ in the brain especially when there is an overabundance of esterified 
cholesterol
 
that decreases membrane lipid turnover [34]. 
Peripheral serum cholesterol levels are also influenced by ApoE genotype [57-59]. In a large sample of healthy 
European men, the ApoE genotypes ε2/2 and ε3/2, ε4/2, ε3/3, ε4/3, and ε4/4 were associated with respectively 
increasing levels of serum total and LDL cholesterol [60]. This relationship may however be disturbed in the 
presence of AD. In a case-control study, cholesterol levels were significantly higher in ApoE4 individuals within 
the control group, whereas no significant relationship was found between ApoE4 and cholesterol in the AD cases 
[40]. 
Hence, we could anticipate that higher plasma cholesterol levels would correlate with higher A aggregation in 
the brain of ApoE4 AD patients.  However, in post-mortem studies of AD patients, higher total cholesterol and 
LDL levels in the blood did correlate with higher A-amyloid levels in the brain but independently of ApoE 
genotype [61]. These correlations were not observed in healthy controls. In epidemiological studies, there is an 
association between higher serum cholesterol levels in midlife and increased risk of
 
AD [62-63] but this 
association was independent of ApoE genotype [62]. Conversely, a decrease in serum total cholesterol from 
midlife to late-life was associated with early stages of dementia, independently of ApoE genotype [64-65]. 
Lower blood cholesterol in later life possibly indicates a poor nutritional status that could be a consequence 
rather than a cause of cognitive decline and dementia. Adding to the controversy, several studies show a 
modification of the association between serum cholesterol level and cognitive performance by ApoE genotype. 
In three cross-sectional studies conducted in various populations, higher plasma total and LDL cholesterol were 
associated with increased AD risk in the non carriers of the ApoE4 allele, whereas cholesterol was not associated 
with increased AD risk in the carriers [66-68]. Similarly, in a cross-sectional study conducted in very old (> 85 
years) non-demented individuals, there was a significant positive correlation between higher total or LDL 
cholesterol and better memory performances in ApoE4 non-carriers [69]. No correlation was observed in ApoE4 
carriers or with HDL cholesterol. The Longitudinal Aging Study Amsterdam yielded controversial results since 
in separate analyses by ApoE status, there was a significant positive association between total cholesterol level 
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and change in information processing speed only in the ApoE4 carriers, suggesting that a higher total cholesterol 
level at baseline was significantly associated with a slower rate of decline in these subjects [70]. A common 
limitation to these studies is the lack of longitudinal data on the interaction between ApoE genotype and change 
in serum cholesterol levels under treatment or dietary modification on the rate of cognitive decline or risk of 
dementia. 
 
 2.3.2  ApoE and fatty acids  
Whereas cholesterol in the brain is produced and regulated endogenously [55], the fatty acid content of neuronal 
membranes can be modulated by dietary intake and ApoE polymorphism in animals [56]. ApoE4 is associated 
with the inhibition of lipid metabolism, inducing inefficient delivery of PUFA, in particular DHA, to neurons 
and altered lipid membrane homeostasis [56]. DHA is the most abundant component of membrane phospholipids 
in the brain. ApoE is a constituent of the TG rich lipoproteins VLDL but there are inconsistencies in the 
literature regarding the essentiality of ApoE in hepatic VLDL synthesis and secretion [71]. After the 
phospholipids, TG are the next richest source of DHA in plasma [72]. The most important role of ApoE in 
lipoprotein metabolism is to be a high-affinity ligand for receptor to the LDL-receptor family and to deliver 
cholesterol to neurons. Although the role of ApoE in brain cholesterol homeostasis is well documented, its 
potential role into fatty acid transport and delivery to the brain is less understood with the exception of 
mentioning that ApoE is important for synaptic plasticity [73]. Hence, at this point, no direct connection between 
ApoE genotypes and fatty acids delivered to the brain is yet possible to establish. This is supported by the data 
obtained by Fraser et al. [74] showing that the relative proportions of fatty acids in frontal, temporal and parietal 
cortex in AD and control brains was not significantly different by ApoE genotype. However, that study 
measured the overall fatty acid composition of the cerebral cortex without regard to subcellular distribution, 
especially in relation to membrane lipid rafts, which is a limitation, particularly for DHA [74]. 
 
3) Modification by ApoE genotype of the effect of dietary n-3 PUFA on cognition 
3.1 Epidemiological studies 
Few epidemiological studies have examined the interaction between n-3 PUFA status and ApoE on cognitive 
decline or risk for dementia or AD. They are summarized in table 1. 
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Table 1. Association between n-3 PUFA and cognitive outcomes stratified by ApoE status in prospective epidemiological studies.  
Reference Exposure Outcome ApoE4 carriers ApoE4 non-carriers 
   N Measure of association 
(95% CI) or P value 
N Measure of association 
(95% CI) or P value 
[75] Fatty fish 
consumption: 
2 to 4 servings per 
week 
8-yr incidence of 
dementia 
474 HR = 0.91 
(0.48 to 1.71) 
1570 HR = 0.60 
(0.40 to 0.89) 
[10] Fish consumption: 
at least once a week 
4-yr incidence of 
dementia 
1479 HR = 1.28 
(0.58 to 2.83) 
 
5944 HR = 0.60 
(0.41 to 0.89) 
 
[76] EPA + DHA in 
plasma cholesteryl 
esters (for 1 SD) 
Cognitive 
decline on Word 
Fluency Test 
650 OR=0.80 
(0.45 to 1.63) 
1601 OR = 0.61 
(0.43 to 0.87) 
 





performance on a 
score derived by 
principal 
38 r = 0.02 
NS 
75 r = 0.35 




[78] EPA and DHA in 
total plasma fatty 






β=0.061, P=.01  
EPA:  
β=0.077, P=.003 
in subjects with low depressive symptoms;  
β=0.172, P<.001 
in subjects with high depressive symptoms. 
984 DHA: 
β=0.001, P=.93  
EPA:  
β=0.001, P=.93 
in subjects with low depressive symptoms;  
β=0.096, P=.04 
in subjects with high depressive symptoms. 
CI = confidence interval 
HR = hazard ratio 
OR = odds ratio 
r = correlation coefficient 
SD = standard deviation 
NS = non significant 
PUFA = poly-unsaturated fatty acid 
EPA = eicosapentaenoic acid 
DHA = docosahexaenoic acid 
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3.1.1 Dietary studies  
The Cardiovascular Health Cognition Study was the first to evidence an interaction with borderline significance 
between consumption of fatty fish and presence of the ApoE4 allele on the risk for AD [75]. Fatty fish appeared 
to have little or no association with risk for AD in those with the ApoE4 but was associated with significantly 
lower risk in those without the ApoE4 allele. Similar results were observed in the French Three-City (3C) study 
which reported a significant protective effect of fish consumption against all-cause dementia only in ApoE4 non-
carriers [10]. However, there was no statistical interaction between fish consumption and ApoE genotype on the 
risk for AD. Moreover, the same study showed a deleterious effect of n-6 rich oils (sunflower or grape seed oil) 
when their consumption was not counterbalanced by consumption of n-3 rich foods (oils or fish) among ApoE4 
non-carriers. This detrimental effect was not observed in ApoE4 carriers. 
Conversely,  among ApoE4 carriers moderate intake of PUFA (2
nd
 quartile) at midlife was associated with 
decreased risk of dementia, while moderate intake of saturated fats was associated with an increased risk in the 
Cardiovascular Risk Factors, Aging, and Incidence of  Dementia (CAIDE) study [79-80]. No association was 
found between intake of fat, whatever its type, and risk of dementia in ApoE4 non-carriers. However, that study 
did not discriminate between n-3 and n-6 PUFA and was therefore not included in table 1. 
 
3.1.2 Biological studies 
 
Most biological studies did not show any interaction between blood n-3 PUFA status and ApoE genotype on 
cognitive evolution in older persons. Indeed, among the five published or in press prospective epidemiological 
studies that examined whether ApoE4 may modify the relationship between long-chain n-3 PUFA blood status 
and dementia or cognitive decline, three [76] [14, 81] did not find any modification effect  and only the first one 
[76] reported data stratified by ApoE status (table 1). In the Atherosclerosis Risk in Communities study [76], an 
inverse association was observed between higher EPA + DHA in plasma cholesterol esters and verbal fluency in 
ApoE4 non-carriers, but not in carriers despite a non-significant interaction term. The lack of significant 
protective association in ApoE4 carriers might therefore be attributed to a lack of power in this smaller 
subgroup. In the Canadian Study of Health and Aging [14], there was no significant modification of risk of 
dementia or AD associated with n-3 PUFA, DHA, or EPA concentrations, treated in quartiles or as continuous 
variables, by ApoE4 status in models adjusted for sex and education (data not shown by the authors and 
therefore not reproduced in Table 1). However, this study found a paradoxical protective association with higher 
blood mercury concentration, which can be considered as a proxy biomarker for fatty fish intake. The presence 
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of both high n-3 PUFA and high mercury concentration was associated with a significantly reduced risk by 43% 
for dementia and by 46% for AD, independently of ApoE genotype [14]. 
Two studies found a statistically significant interaction (table 1), with a protective effect in ApoE4 non-carriers 
only in one study [77] and conversely, a protective association only in ApoE4 carriers in the other study [78]. In 
the first study, children aged 11 years old with higher general intelligence had higher erythrocyte n-3 PUFA, but 
the correlation was significant only for those without the ApoE4 allele [77]. The same population was retested at 
64 years old and their general intelligence was even more highly positively correlated with erythrocyte n-3 
PUFA, but there was still no correlation in ApoE4carriers. The 3C study yielded inverse results since higher 
plasma EPA and DHA proportions were associated with slower decline in working memory assessed by Benton 
Visual Retention Test among ApoE4 carriers only [78]. Decline of performance in other cognitive domains (i.e 
global cognition, executive functioning and verbal fluency) was not related to plasma long-chain n-3 PUFA 
content, neither in the whole sample nor according to ApoE4 carrier status. Notably, in that study, baseline 
plasma EPA and DHA proportions did not differ according to ApoE genotype. 
 
3.2 Intervention studies 
One recent study evaluating the impact of fish oil on cognitive performance in the healthy elderly reported that 
after 26 weeks of supplementation with either 0.4 or 1.8 g/d of long-chain n-3 PUFA ApoE4 carriers had 
improved scores on tests of the cognitive domain of attention compared to the placebo contrarily to non-carriers 
[18]. Plasma EPA and DHA concentrations were given but no information was provided as to whether they 
changed differentially in relation to ApoE4 genotype. 
Conversely, the unpublished results of a randomized controlled trial (RCT) comparing DHA (2 g/d) and placebo 
conducted by the National Institutes on Aging Alzheimer’s Disease Cooperative Study Unit in mild to moderate 
AD which was presented at the International Conference on Alzheimer’s disease 2009 [82] and reported by 
Joseph et al. [83] and Cole et al. [84], mentioned possible but non-significant slowing of progression of cognitive 
decline in ApoE3, but no effect in ApoE4 carriers. In the Memory
 
Improvement with DHA Study (MIDAS) 
RCT, improved learning and episodic memory functions were observed in older adults with mild memory 
complaints receiving 900 mg algal DHA per day but the publication does not mention whether ApoE genotype 
was taken into account [22]. 
Post-hoc analyses of RCT in small subgroups must be considered with caution when the randomisation was not 
stratified according to ApoE genotype. Analyses according to ApoE genotype should be systematically planned 
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in the protocol of trials of dietary supplementation with n-3 PUFA for the primary or secondary prevention of 
cognitive decline in AD. 
 
4) Putative mechanisms underlying this interaction 
4.1 Impaired fatty acids transport to the brain  
The link between the way EPA and DHA are transported and cognition may involve delivery of fatty acids for 
membrane repair and signalling pathways within the brain. It is suggested that DHA-enriched LDL are taken up 
more efficiently by the brain than other lipoproteins [85-86], whereas others suggest that it is the unesterified 
form of DHA that most efficiently reaches the brain [87-88]. One major limitation to the delivery of fatty acids 
to the human brain is to cross the blood brain barrier. Two general models have been proposed: the first 
approach suggests a passive diffusion of unesterified plasma fatty acids [87-89] while the second suggests uptake 
of lipoproteins via a receptor-mediator process, likely the LDL-receptor [86, 88]. Since ApoE is the main ligand 
for LDL-receptor protein in the central nervous system [53] and that the 4 allele seems to impact the efficiency 
of the binding of ApoE with the LDL-receptor, it is hence possible that the delivery of EPA and DHA to the 
brain is altered in ApoE4 carriers. However, this hypothesis yet has to be investigated in mice expressing human 
ApoE4.  
  
4.2 Modification by ApoE of the effect of dietary EPA and DHA on blood lipids 
Another mechanism explaining the interaction between dietary PUFA and ApoE genotype on rate of cognitive 
decline and risk for AD may lie in a modification by ApoE of the effect of EPA and DHA intake on blood lipid 
profile. 
 
4.2.1. Modification by ApoE of the effect of dietary EPA and DHA on plasma fatty acid profile 
A gene-by-diet interaction has recently been reported for the incorporation of EPA and DHA into plasma lipids 
of ApoE4 carriers and non-carriers [90]. The plasma fatty acid profiles of 8 carriers and 20 non-carriers of 
ApoE4 showed that ApoE4 carriers had significantly higher EPA and DHA in plasma TG at baseline [90]. 
However, after receiving a supplement of 1.9 g/d of EPA and 1.1g/d of DHA for 6 weeks, there were significant 
gene-by-diet interactions in the incorporation of both EPA in free fatty acids and DHA in plasma TG such that in 
carriers of ApoE4, increases in the two fatty acids was lower compared to the non-carriers [90]. The mechanism 
underlying the gene-by-diet interaction is possibly linked with the way EPA and DHA are transported by 
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lipoproteins. After dietary intake, most dietary lipids are transported by chylomicrons but small amounts 
circulate in the blood stream as free fatty acids bound to albumin. Chylomicrons are TG-rich lipoproteins 
produced in intestinal cells after the intake of a meal, while lipoproteins are produced by hepatic cells. All 
lipoproteins, with the exception of HDL, begin as molecules rich in TG. VLDL is the most TG-rich lipoprotein, 
which through sequential lipolysis of TG by lipoprotein lipase leads to the formation of LDL. Although many 
studies report the incorporation of EPA and DHA into blood total lipids, phospholipids, TG, cholesteryl esters or 
red blood cells, there are only a few studies that report how EPA and DHA are transported in the blood and how 
much is incorporated into each type of lipoprotein. In studies of supplementation with EPA + DHA, both fatty 
acids were incorporated into VLDL-, LDL- and HDL-TG within 4h after fish-oil intake [91-93]. Altogether, the 
limited number of available studies suggests that DHA is rapidly and preferentially incorporated into TG fraction 
of most lipoproteins after its intake, and that within a few hours its concentration tends to decrease. Hence, the 
metabolism of EPA and DHA is most of the time in transition and the lap of time of this transition may be 
altered by ApoE4 genotype. However, to our knowledge, no studies have evaluated the impact of ApoE4 
genotype on the transport of EPA and DHA by lipoproteins.  
 
4.2.2. Modification by ApoE of the effect of EPA and DHA on blood cholesterol  
Some of the modifying effect of ApoE genotype on the relationship between dietary n-3 PUFA and risk of AD 
might be mediated through cholesterol. Indeed, blood cholesterol concentration is partly determined by dietary 
intake of n-3 and n-6 PUFA [94] but also by genetics, in particular ApoE polymorphism. A gene-nutrient 
interaction might therefore be expected. 
Carriers of ApoE4 have been shown to have a greater lipid response to dietary changes [95]. In 2003, a 
systematic review of the literature reported the effect of genetic variation, including ApoE polymorphism, on the 
lipid response to dietary intervention [96]. The authors reviewed intervention studies to modify dietary 
cholesterol, dietary fat or other compounds of the diet. Of the 46 interventions that modified the fat composition 
of the diet, 15 found significantly different total, LDL- and HDL-cholesterol responses, with carriers of the 
ApoE4 allele tending to be the most responsive to changes in dietary fat. Recently, others have reported a gene-
by-diet interaction such that total cholesterol in ApoE4 carriers was increased following DHA supplementation, 
which is possibly due to an increase in LDL-cholesterol [97]. In plasma VLDL2 fraction of ApoE4 carriers, 
intake of DHA resulted in a significant 32% reduction in LDL uptake relative to control supporting alterations in 
the transport and uptake of lipoproteins [97]. However, this study did not investigate whether the incorporation 
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of DHA into the different types of lipoproteins was different based on ApoE4 genotype, so whether the possible 
changes are at the root of the LDL uptake differences still needs further investigations. 
Altogether, these data suggest that ApoE genotype interacts with dietary PUFA in the transport and uptake of 
lipoproteins, thereby changing cholesterol levels. 
 
4.2.3 Modification by ApoE of the effect of EPA and DHA on blood TG 
A major effect of dietary n−3 PUFA on plasma lipids is a reduction of the concentration of plasma TG [98], an 
effect that may be modified by ApoE genotype. A study in healthy elderly Brazilian women showed higher TG 
serum levels in ε2 compared to ε4 carriers [99]. However, in the presence of high spontaneous intake of total fat 
or a low relative intake of PUFA, ApoE4 carriers lost protection against hypertriglyceridemia [99]. 
Administration of fish oil in a RCT showed a double treatment by sex by ApoE genotype interaction [100]. 
Indeed, the greatest decreases in TG concentration with either 0.7 g EPA+DHA/d or 1.8 g EPA+DHA/d were 
observed in ApoE4 males.  
High TG are linked to cognitive decline and risk of dementia. An experimental study in obese mice showed that 
lowering TG can reverse their cognitive impairment [101]. In the 3C study we showed an association between 
hypertriglyceridemia and increased risk of all-cause and vascular dementia [102]. However, this effect was 
independent of ApoE4 genotype. 
N-3 PUFA could therefore contribute to lower the risk of cognitive impairment and dementia associated with 
high TG in ApoE4 carriers. However, the potential modifying effect of ApoE genotype on this relationship still 
lacks scientific support. 
 
4.2.4 Modification by ApoE of the susceptibility to lipid peroxidation 
As discussed in section 2.1, ApoE4 carriers have a lower activity of defence mechanisms against oxidative 
stress. One hypothesis to explain why ApoE4 carriers are not protected against risk of cognitive decline by fish 
or DHA intake is possibly linked to their altered LDL metabolism leading to higher susceptibility to peroxidation 
[103]. Lipids are needed to repair neuronal membrane and ApoE4 genotype apparently fails to protect lipids 
from peroxidation. Therefore, the oxidised lipids needed to be removed from damaged neuronal membranes are 
possibly replaced by other oxidised lipids [103].  Moreover, formation of lipid peroxidation products may 
contribute to tau protein phosphorylation in AD [104]. Since EPA and DHA are susceptible to oxidation because 
they are highly unsaturated, their transport via LDL is thus possibly more vulnerable to oxidation in ApoE4 
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carriers. The residence time of LDL in ApoE4 carriers may also be longer since ApoE is the main ligand to the 
LDL-receptor in the periphery and that carrying the 4 allele lowers the binding of ApoE to its LDL-receptor 
[71, 96]. The higher peroxidation of lipoproteins in ApoE4 carriers may hence contribute to their higher risk of 
AD. 
  
4.3 Modification by ApoE of the effect of dietary EPA and DHA on other risk factors of dementia  
Presence of the ApoE4 might accelerate the rate of cognitive decline through changes in the level of both AD 
pathology and vascular injury [1]. Inflammation and metabolic disorders belong to the large set of factors that 
contribute to the accumulation of neuro-pathological and vascular changes in late-life dementia [1]. N-3 PUFA 
may decrease the negative impact of these risk factors and enhance compensatory repair mechanisms [23]. In 
addition to its direct effects on lipid metabolism discussed above, ApoE genotype might also modulate the 
impact of dietary n-3 PUFA on inflammation, vascular risk factors and overall nutritional status. However, very 
few studies have analysed the interaction between EPA, DHA and ApoE genotype on these risk factors of 
dementia. The aim of this more speculative section is to raise new hypotheses that would deserve further 
research. 
 
 4.3.1 Inflammation 
N-3 PUFA have potent anti-inflammatory properties [4]. Indeed, EPA is the precursor of anti-inflammatory 
eicosanoids and DHA is the precursor of neuroprotectin D1 (NPD1). NPD1 represses the activation of 
inflammatory signalling
 
mediators such as prostaglandins synthesized from arachidonic
 
acid (long-chain n-6 
PUFA) by cyclooxygenase-2 [3]. 
As discussed in section 2.2, some studies suggest that inflammatory status might also be modulated by ApoE 
genotype. In the Cardiovascular Health Cognition Study, the reduction in risk for AD associated with use of non-
steroidal anti-inflammatory drugs was greater among ApoE4 carriers [105]. Hence, ApoE4 carriers might also 
have an enhanced response to the anti-inflammatory effects of n-3 PUFA. This hypothesis was investigated in a 
small subsample of the OmegAD RCT which evaluated the impact of a supplementation with 2320 mg 
EPA+DHA /d on cognitive functioning in patients with mild to moderate AD [21, 106]. However, plasma 
biomarkers of inflammation (interleukin-6, tumor necrosis factor-, CRP) did not differ between the intervention 
and placebo groups nor was there any difference for inflammation markers in cerebrospinal fluid. There was no 
interaction with ApoE genotype indicating a similar lack of impact of n-3 PUFA supplementation on biomarkers 
 19 
of inflammation in ApoE4 carriers and non-carriers. However, this was a very small study (N=35) and the 
potential differential effect of n-3 PUFA on inflammation according to ApoE genotype still deserves further 
research. 
 
 4.3.2 Glucose metabolism 
During healthy aging, brain glucose uptake may decrease significantly in specific cortical regions [107], an 
effect that may be more pronounced in the elderly with deteriorating cognitive function such as AD [108]. 
Reduction of cerebral metabolic rates for glucose was also found in asymptomatic ApoE4 carriers as young as 20 
to 30 years old in the same brain regions as clinically affected AD patients [109]. These results are the earliest 
sign of brain hypometabolism abnormality yet found in living person at risk of AD and suggest that in ApoE4 
carriers, hypometabolism precedes the onset of clinical AD and is not a consequence of the disease itself. 
Glucose is the main cerebral energy substrate and during fasting or low carbohydrate intake ketones are 
glucose’s primary replacement fuel [110]. Hence, in the elderly and in ApoE4 carriers, increasing blood ketones 
and potentially their uptake by the brain may be a good strategy to counterbalance their lower brain glucose 
uptake. The capacity to produce ketones seems similar in the elderly (>70 y old) compared to the young 
(between 18-25 y old) and is potentially not depending upon ApoE genotype [111]. Higher blood ketones 
facilitated cognitive performance in ApoE4 non-carriers but not in the carriers [112]. Similar results in a larger 
scale study with 152 subjects diagnosed with mild to moderate AD confirmed that higher ketone levels in ApoE4 
carriers had no specific changes in the scores of cognitive tests [113]. Whether increasing blood ketones 
improves cognition by raising brain uptake of ketone bodies needs investigation.  
 
 4.3.3 Hyperhomocysteinemia 
Elevated serum homocysteine is a cardiovascular risk factor which is also associated with increased risk of 
cognitive decline [114-116], dementia [116-118] and AD [117-119]. Surprisingly, ApoE4 carriers tend to have a 
lower risk of hyperhomocysteinemia [49]. The presence of the ApoE4 allele also modified the relationship 
between hyperhomocysteinemia and cognitive performance in one study: the inverse association between total 
homocysteinemia and cognitive scores was consistently higher in ApoE4 carriers [120]. 
There is an inverse association between plasma homocysteine and platelet phospholipid DHA concentration 
[121]. Administration of fish oil significantly decreased plasma homocysteine in rats [122] and hyperlipemic 
men [123]. Conversely, DHA concentration may be affected by homocysteine concentration [124]. However, to 
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our knowledge, no published study examined the impact of ApoE genotype on the link between homocysteine 
and DHA in AD. 
 
4.3.4 Obesity 
There is increasing evidence that obesity at midlife is a risk factor for cognitive impairment [125-126] and 
dementia [127-130] later in life, although the latter association became non significant after further adjustment 
for vascular disorders and ApoE4 status in one study [130]. Obesity contributes to maintain a chronic 
inflammatory status.  In vitro, DHA inhibits the differentiation of pre-adipocytes to adipocytes [131]. In obese 
adults, there was an inverse correlation between total n-3 PUFA, EPA and body mass index (BMI) which was 
not observed in normal weight individuals [132]. Moreover, obese individuals had lower n-3 PUFA 
concentrations which might contribute to their increased risk of cognitive decline.  
However, the link between ApoE genotype, obesity, n-3 PUFA and dementia risk is not yet clearly established. 
Indeed, a recent review concluded that few studies have attempted to link human ApoE isoforms to obesity, and 
they have produced somewhat conflicting results [133]. Obesity results from an imbalance between energy 
intake and actual needs. One study evidenced an interaction between high energy intake  and ApoE4 on the risk 
of dementia. Indeed, in the WHICAP higher calorie intake was associated with increased risk of AD only in 
those who had at least one ApoE4 allele [134]. High total fat intake was also associated with increased risk for 
AD in the same individuals. However, the modulating effect of n-3 PUFA on these relationships was not studied. 
Further research is therefore needed to understand how ApoE genotype could modulate the impact of n-3 PUFA 
on obesity and subsequent cognitive decline. 
 
4.3.5 Global nutritional status 
In older adults there is a U-shaped association between BMI and dementia, with increased dementia risk in obese 
and underweight individuals [135]. Poor nutritional status is associated with higher risk of dementia in older 
persons [135-137]. 
Although the underlying mechanisms are not clear, nutritional status may be associated with ApoE genotype. 
Surprisingly, in the Cache
 
County Study on Memory and Aging participants with a diet that provided
 
a greater 




to have at least one copy of the 4 allele than were those with 
less varied diets [138]. This finding may be explained by selective survival of individuals whose healthy diet 
may have contributed to reverse the negative selection pressure associated with ApoE4. The quality of the diet 
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would be less essential for the survival of ApoE4 non-carriers. Significant weight loss and decrease in BMI were 
observed in older women with AD who were ApoE4 carriers but not in non-carriers [139]. In cognitively normal 
control women, no significant weight loss was observed whatever the ApoE4 status. 
In AD patients included in the OmegAD RCT, weight gain and appetite improved in the EPA+DHA group 
independently of the ApoE genotype [140]. Not carrying the ApoE4 allele and higher DHA plasma levels during 
the treatment period were both positively associated with weight gain. Unfortunately, the same study did not 
report the differential effects of n-3 PUFA supplementation on cognition according to ApoE genotype [21]. 
Hence, DHA and/or EPA might also work through mechanisms that could contribute to improve overall 
nutritional status of AD patients. This effect might be modulated by ApoE4 genotype but the direction and 
magnitude of the interaction is not yet clearly established. 
 
 
4.3.6 Mood  
 
Older persons with depressive symptoms are at higher risk of cognitive decline and AD [141-143]. Moreover, 
several studies have reported an association between the ApoE4 allele and depression among older adults [144]. 
Studies examining the impact of long-chain n-3 PUFA on depressive symptoms have provided mixed results. 
While observational epidemiological studies suggest a protective effect of EPA and DHA [145-148] or fish 
consumption [147, 149-150] in various mood disorders, most RCT failed to evidence a significant impact of 
supplementation with EPA or DHA [19, 151-152] with some interesting recent exceptions [153]. This lack of 
apparent efficiency may be explained in part by a differential effect of n-3 PUFA according to ApoE genotype 
which could mask a protective association in some individuals. In the 3C study, higher plasma EPA was 
associated with slower decline on Benton Visual Retention Test in ApoE4 carriers, or in subjects with high 
depressive symptoms at baseline [78]. Both interactions were independent, i.e. the highest protective effect was 
observed in depressive ApoE4 carriers. This finding suggests that the impact of n-3 PUFA on cognition in 
ApoE4 carriers is mediated by more than a decrease in depressive symptoms. 
In the OmegAD RCT, no significant overall treatment effects on neuropsychiatric symptoms of AD patients 
were found [154]. However, significant positive treatment effects on the scores in the Neuro-Psychiatric 
Inventory agitation domain in ApoE4 carriers and on the Montgomery-Asberg Depression Rating Scale in 
ApoE4 non-carriers were found. Such inconsistent results emphasize the need for further research on the 
mechanisms underlying the effect of n-3 PUFA on mood disorders in AD patients according to ApoE genotype 
and their potential impact on subsequent cognitive decline. 
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5) General discussion and conclusion 
As suggested in a recent review, the presence of the ApoE4 allele might alter the course of late-life cognitive 
decline through changes in levels of both AD pathology and vascular injury, as well as through modifications in 
compensatory repair mechanisms [1]. AD likely occurs when many contributing risk factors, including genetics, 
converge and are counterbalanced by few protective factors [155]. Dietary n-3 PUFA are now understood to 
modify some of these risk factors. The ApoE4 interaction with PUFA metabolism is a nutrient-gene interaction 
which must be taken into account when assessing the risk for AD and evaluating the impact of dietary intake or 
supplementation with n-3 PUFA. Statistical analyses should systematically search for interactions with, and not 
only adjust for, ApoE genotype. In case of a significant interaction, stratified analyses should be provided. 
The reasons why some effects of n-3 PUFA are observed in the ApoE4 carriers and others in non-carriers, as 
summarized in table 2, are not yet fully understood. It has been suggested that ApoE4 carriers may be more 
vulnerable to environmental factors [80] because of compromised brain reserve [156] or poor brain protection 
and repair mechanisms. Indeed, ApoE4 carriers have higher serum total and LDL cholesterol, impaired brain 
metabolism, and more often depressive symptoms. Nevertheless, ApoE4 carriers often have a lower level of 
some risk factors related to cognitive decline or dementia such as inflammation, hyperhomocysteinemia, and 
overweight, with inconsistent results. When considering the impact of dietary supplementation with n-3 PUFA 
on these biomarkers, ApoE4 carriers tend to be more responsive but few data are available from epidemiological 
or intervention studies. Paradoxically, ApoE4 carriers are less sensitive to the protective effects of n-3 PUFA on 
cognition in most studies. Further research is needed to understand the patho-physiological mechanisms 
underlying the differential effect of dietary PUFA on AD risk or cognitive decline according to ApoE genotype 
in order to better target intervention studies and nutritional recommendations on potential beneficiaries. 
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Table 2. Impact of n-3 PUFA on risk factors of dementia and AD according to ApoE genotype: summary of 
findings. 
 
Effect of dietary n-3 PUFA on: 
 
Stronger effect of n-3 PUFA in: 
ApoE4 carriers ApoE4 non-carriers 
Incorporation of EPA and DHA in 
blood TG 
 X 
Blood total, LDL or HDL cholesterol X  
Lowering blood TG concentration  X  
Increasing susceptibility to lipid 
peroxidation 
X  
Lowering inflammation = = 
Lowering homocysteine concentration ? ? 






Improving depressive symptoms  X 
 
Legend: 
X stronger effect 
= similar effect in both groups 
? unknown or discordant results 
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List of abbreviations 
AD  Alzheimer’s disease 
ApoE  Apolipoprotein E 
ApoE4  4 allele of the Apoliprotein E gene 
BMI   Body mass index 
CAT  Catalase 
CRP  C-reactive protein 
DHA  Docosahexaenoic acid 
EPA  Eicosapentaenoic acid 
GSH-Px  Glutathion peroxidase 
HL  Hepatic lipase 
IDL  Intermediate density lipoproteins 
LDL  Low density lipoprotein 
LPL  Lipoprotein lipase 
MRI  Magnetic resonance imaging 
n-3   Omega-3 
n-6   Omega-6 
PET  Positron emitting tomography 
PIB  Pittsburgh compound B 
PUFA  Poly-unsaturated fatty acids  
RCT  Randomized controlled trial 
ROS  Reactive oxygen species 
TG   Triglycerides 
VLDL  Very low density lipoprotein 
WHICAP  Washington Heights-Inwood Columbia Aging Project 
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